BBNX Stock Forecast: Beta Bionics, Inc. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $25 — +87.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (61): Sales and profits are climbing, and climbing faster than before.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BBNX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +87.1% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Piper Sandler | Reiterates | Overweight | $20 → $24 |
| 28 Oct 2026 | TD Cowen | Maintains | Hold | $18 → $21 |
| 12 Oct 2026 | Jefferies | Initiates | Buy | $30 |
| 24 Sept 2026 | Truist Securities | Maintains | Buy | $23 → $28 |
| 23 Sept 2026 | Wells Fargo | Initiates | Overweight | $28 |
| 15 Sept 2026 | B of A Securities | Maintains | Neutral | $18 → $20 |
| 15 Sept 2026 | Baird | Maintains | Neutral | $14 → $16 |
| 15 Sept 2026 | Truist Securities | Reiterates | Buy | $22 → $23 |
| 14 Sept 2026 | Leerink Partners | Maintains | Outperform | $24 → $27 |
| 21 Aug 2026 | William Blair | Initiates | Market Perform | — |
| 28 July 2026 | UBS | Assumes | Buy | $22 |
| 15 July 2026 | Goldman Sachs | Maintains | Buy | $17 → $19 |
| 13 July 2026 | Truist Securities | Maintains | Buy | $18 → $22 |
| 27 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 May 2026 | B of A Securities | Maintains | Neutral | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 Apr 2026 | Stifel | Maintains | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 Feb 2026 | Baird | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BBNX.
This page is one stock. Monday covers all of them.
BBNX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BBNX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Beta Bionics, Inc. returned −53.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BBNX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.7×
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 19% of US stocks
Cheaper than 48% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 59.0%
- Operating margin
- −72.7%
- Net margin
- −65.3%
Higher than 72% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
- Return on equity
- −23.9%
- Return on assets
- −15.0%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Beta Bionics, Inc. has a market value of $724.2M and an enterprise value of $490.1M.
Revenue in the twelve months to 30 June 2026: $119.0M. The latest quarter grew 37.8% year on year.
Net income over the same four quarters: −$73.0M, a −61.3% net margin.
Diluted earnings per share, trailing twelve months: −$1.65.
Free cash flow in the twelve months to 30 June 2026: −$61.4M.
Beta Bionics, Inc. employs 420 people — $283K of revenue per employee.
Data provided by Twelve Data
BBNX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BBNX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BBNX
What is the BBNX stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $25, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BBNX stock a buy right now?
Of the 15 analysts covering Beta Bionics, Inc., 11 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BBNX?
As at 21 Nov 2026, Beta Bionics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (61 of 100).
Will BBNX stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +87.1% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BBNX stock forecast for 2030?
No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.
How has BBNX stock performed over the past year?
Beta Bionics, Inc. returned -53.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Beta Bionics, Inc. do?
Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes. Its core product, the iLet Bionic Pancreas, is designed to simplify day-to-day diabetes management by using adaptive closed-loop algorithms to determine insulin dosing.
About Beta Bionics, Inc.
Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes. Its core product, the iLet Bionic Pancreas, is designed to simplify day-to-day diabetes management by using adaptive closed-loop algorithms to determine insulin dosing. Beta Bionics offers systems and related solutions for adults and children with type 1 diabetes, alongside supporting software and connected tools that help streamline treatment workflows. The company operates in the diabetes technology and medical devices markets, where it addresses the needs of patients, caregivers, and healthcare providers seeking more integrated insulin management solutions. Headquartered in Irvine, California, Beta Bionics plays a role in advancing device-based diabetes care through commercially available products centered on automated insulin delivery.
CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com